Background:68Gallium DOTA-PET imaging is preferable to standard somatostatin receptor scintigraphy where available; however, its role in the management of lung carcinoid tumours (LC) remains unclear. Methods: All consecutive patients with histologically confirmed LC from two ENETS Centres of Excellence were identified retrospectively. The primary objective was to assess the impact of 68Ga-DOTANOC-PET on clinical management in patients with LC. Results: Of 166 patients screened, 46 were eligible: 52% female, median age 57 years (range 21-86); type of LC: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (4%), typical (44%), atypical (35%), not reported (17%); stage: localised (63%), locally advanced (13%), and metastatic (17%) (7% unknown). A total of 47 68Ga-DOTANOCs were performed with the following rationale: LC diagnosis confirmation (4; 9%), primary tumour identification (2; 4%), post-surgical assessment (19; 40%), staging (patients with known LC present at time of 68Ga-DOTANOC) (19; 40%), and consideration of peptide receptor radionuclide therapy (3; 7%). Twenty-seven (57%) scans showed evidence of non-physiological uptake: median maximum standardised uptake value 7.2 (range 1.42-53). 68Ga-DOTANOC provided additional information in 37% (95% CI 22-51) of patients and impacted on management in 26% (95% CI 12-41); 9 patients (21%) were identified to have occult sites of metastases. Out of the 19 patients with post-surgical 68Ga-DOTANOC, 3 (16%) were identified to have distant metastases. There were no differences in the rate of practice changing 68Ga-DOTANOC results by type of LC (p value 0.5). Conclusions: Our results support the role of 68Ga-DOTANOC for optimising the management of patients with LC, including post-surgical re-staging due to the potential for identifying occult metastases.

1.
Travis WD: The concept of pulmonary neuroendocrine tumours; in Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (eds): Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, IARC Press, 2004, p 19.
2.
Pelosi G, Fabbri A, Cossa M, Sonzogni A, Valeri B, Righi L, Papotti M: What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms? Semin Diagn Pathol 2015;32:469-479.
3.
Chauhan A, Ramirez RA: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and the role of somatostatin analogs: a case series. Lung 2015;193:653-657.
4.
Marchevsky AM, Walts AE: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH). Semin Diagn Pathol 2015;32:438-444.
5.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after “carcinoid” epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
6.
Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001;92:2204-2210.
7.
Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959.
8.
Tang LH, Basturk O, Sue JJ, Klimstra DS: A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol 2016;40:1192-1202.
9.
Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T: Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015;22:657-664.
10.
Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, Campanini N, Carbognani P, De Pas TM, Galetta D, Granone PL, Righi L, Rusca M, Spaggiari L, Tiseo M, Viale G, Volante M, Papotti M, Pelosi G: Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 2013;21:1-16.
11.
Pelosi G, Papotti M, Rindi G, Scarpa A: Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. Endocr Pathol 2014;25:151-164.
12.
Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD: Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 2015;26:1604-1620.
13.
Horsch D, Schmid KW, Anlauf M, Darwiche K, Denecke T, Baum RP, Spitzweg C, Grohe C, Presselt N, Stremmel C, Heigener DF, Serke M, Kegel T, Pavel M, Waller CF, Deppermann KM, Arnold R, Huber RM, Weber MM, Hoffmann H: Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany. Oncol Res Treat 2014;37:266-276.
14.
Aparicio T, Ducreux M, Baudin E, Sabourin JC, de BT, Mitry E, Schlumberger M, Rougier P: Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001;37:1014-1019.
15.
Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J: The clinical value of (90Y-DOTA)-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-945.
16.
Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Macke HR, Rochlitz C, Muller-Brand J, Walter MA: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue (90Y-DOTA)-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416-2423.
17.
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van EM, Kooij PP, Feelders RA, van Aken MO, Krenning EP: Treatment with the radiolabeled somatostatin analog (177 Lu-DOTA 0, Tyr3)octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-2130.
18.
van EM, Krenning EP, Bakker WH, de Herder WW, van Aken MO, Kwekkeboom DJ: Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007;34:1219-1227.
19.
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Delle FG, Van CE, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016;387:968-977.
20.
Lococo F, Cesario A, Paci M, Filice A, Versari A, Rapicetta C, Ricchetti T, Sgarbi G, Alifano M, Cavazza A, Treglia G: PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. Tumour Biol 2014;35:8369-8377.
21.
Lococo F, Treglia G, Cesario A, Paci M, Filice A, Versari A, Filosso PL: Functional imaging evaluation in the detection, diagnosis, and histologic differentiation of pulmonary neuroendocrine tumors. Thorac Surg Clin 2014;24:285-292.
22.
Abgral R, Leboulleux S, Deandreis D, Auperin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de BT, Guigay J, Ducreux M, Schlumberger M, Baudin E: Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (>/ = 10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 2011;96:665-671.
23.
Park CM, Goo JM, Lee HJ, Kim MA, Lee CH, Kang MJ: Tumors in the tracheobronchial tree: CT and FDG PET features. Radiographics 2009;29:55-71.
24.
Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR: The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007;131:255-260.
25.
Pattenden HA, Leung M, Beddow E, Dusmet M, Nicholson AG, Shackcloth M, Mohamed S, Darr A, Naidu B, Iyer S, Marchbank A, Greenwood A, West D, Granato F, Kirk A, Ariyaratnam P, Loubani M, Lim E: Test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumours. Thorax 2015;70:379-381.
26.
Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De CC, Chiti A: Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37:2004-2010.
27.
Sollini M, Erba PA, Fraternali A, Casali M, Di Paolo ML, Froio A, Frasoldati A, Versari A: PET and PET/CT with 68gallium-labeled somatostatin analogues in non GEP-NETs tumors. ScientificWorldJournal 2014;2014:194123.
28.
Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES: The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging 2014;4:426-434.
29.
Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J: Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med 2017;58:91-96.
30.
Ambrosini V, Nicolini S, Caroli P, Nanni C, Massaro A, Marzola MC, Rubello D, Fanti S: PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol 2012;81:988-1001.
31.
Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al HM, Toumpanakis C, Almukhailed O, Kayani I, Syed R, Navalkissoor S, Ell PJ, Caplin ME, Bomanji J: The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom. J Nucl Med 2016;57:34-40.
32.
Venkitaraman B, Karunanithi S, Kumar A, Khilnani GC, Kumar R: Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging 2014;41:856-864.
33.
Phan AT, Oberg K, Choi J, Harrison LH Jr, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ: NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010;39:784-798.
34.
National Comprehensive Cancer Network: National Comprehensive Cancer Network (NCCN) Guidelines. Washington, National Comprehensive Cancer Network, 2016.
35.
Edge SB, et al (eds): AJCC Cancer Staging Manual, ed 7. Berlin, Springer, 2010.
36.
Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB: A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50:1927-1932.
37.
Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A, Dutta R: Evaluation of the role of (18F)FDG-PET/CT and (68Ga)DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging 2011;11:70-75.
38.
Jindal T, Kumar A, Venkitaraman B, Dutta R, Kumar R: Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids. Korean J Intern Med 2010;25:386-391.
39.
Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, Montini GC, Mattioli S, Grassetto G, Al-Nahhas A, Franchi R, Fanti S: 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30:281-286.
40.
Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wangler B, Uebleis C, Schmidt GP, Goke B, Bartenstein P, Hacker M: The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 2012;53:1686-1692.
41.
Souvatzoglou M, Ziegler SI, Martinez MJ, Busch R, Dzewas G, Schwaiger M, Bengel F: Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging 2007;34:405-412.
42.
Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S: (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37:722-727.
43.
Oksuz MO, Winter L, Pfannenberg C, Reischl G, Mussig K, Bares R, Dittmann H: Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging 2014;95:289-300.
44.
Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM: Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 2015;42:5-19.
45.
Mariniello A, Bodei L, Tinelli C, Baio SM, Gilardi L, Colandrea M, Papi S, Valmadre G, Fazio N, Galetta D, Paganelli G, Grana CM: Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging 2016;43:441-452.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.